Booking Holdings Inc vs Cassava Sciences Inc — how do they compare? Booking Holdings Inc trades at $175.44 (market cap $136.22B), while Cassava Sciences Inc trades at $1.09 (market cap $56.04M). The key difference: Booking Holdings Inc is far larger — about 2430.8× Cassava Sciences Inc's market cap, and Booking Holdings Inc pays a 0.91% dividend while Cassava Sciences Inc pays none. Which is the better fit depends on your goals.
| BKNG | FLNA | |
|---|---|---|
Market Cap | $136.22B | $56.04M |
Sector | Consumer Cyclical | Health |
52-Week High | $231.02 | $4.64 |
52-Week Low | $154.13 | $1.09 |
Enterprise Value | $139.14B | -$30.54M |
Dividend Yield | 0.91% | — |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
FLNA trades at $1.15, down 2.54% on the day, with a bearish technical signal from moving averages but neutral oscillators. The company continues to report losses, with a net income of -$90.97M in 2025 and negative cash flow, though it has beaten EPS estimates for the last three quarters. Recent news highlights ongoing development in its TSC-related epilepsy therapies.
Despite consistent earnings beats, FLNA's negative profitability and cash burn pose significant risks. Analyst sentiment is positive with a 66.7% buy rating, but the stock's outlook depends heavily on clinical success and future funding. Investors should weigh the high-risk, high-reward nature of this biotech play.
Trailing returns across standard periods
Booking is the world's largest online travel agency by revenue, offering booking and payment services for hotel and alternative accommodation rooms, airline tickets, rental cars, restaurant reservations, cruises, experiences, and other vacation packages. The company operates a number of branded travel booking sites, including Booking.com, Agoda, OpenTable, and Rentalcars.com, and has expanded into travel media with the acquisitions of Kayak and Momondo. Transaction fees for online bookings account for the bulk of revenue and profits.
Read more on BKNG →Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease
Read more on FLNA →